DOCSLIB.ORG

Stock Available with Stock Position

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Stock Available with Stock Position scode generic measurement Formulation Stock Available [Customer Demand Annualy] Annual Consumption A003 ACETYLSALICYLIC ACID 300MG TABLET 3,170 12,240 4,177 A017 ANTACID CHEWABLE TABLETS TABLET CHEWABLE 221,950 646,560 386,286 A022 BACLOFEN 10MG TABLET 64,848 483,732 319,924 A038 CALCIUM LACTATE 300MG TABLET 266,000 1,797,612 1,172,351 A042 CARBIDOPA|LEVODOPA 10MG|100MG TABLET 145,200 1,661,940 1,560,315 A043 CARBIDOPA|LEVODOPA 25MG|250MG TABLET 2,850 A062 CLOMIPRAMINE HYDROCHLORIDE 25MG TABLET 320,000 1,731,612 976,556 A063 COLCHICINE 500µ TABLET 49,254 314,412 171,971 A073 DAPSONE 50MG TABLET 13,552 22,668 12,395 A077 DIGOXIN 0.0625MG TABLET 313,936 1,313,736 827,752 A089 DYDROGESTERONE 10MG TABLET 2,520 7,128 2,234 A094 ETHAMBUTOL HYDROCHLORIDE 400MG TABLET 3,864 15,012 9,882 A112 FRUSEMIDE 40MG TABLET 175,700 872,880 479,257 A113 FUSIDATE SODIUM 250MG TABLET 2,300 9,888 5,318 A115 GLYCERYL TRINITRATE 500µ TABLET 36,340 578,364 324,289 A119 HALOPERIDOL 0.5MG CAPSULE 49,448 363,552 429,849 A137 ISOSORBIDE DINITRATE 10MG TABLET 338,080 1,005,972 386,600 A149 LOPERAMIDE HYDROCHLORIDE 2MG CAPSULE 19,900 229,284 116,993 A154 MEDROXYPROGESTERONE ACETATE 5MG TABLET 1,000 5,592 3,626 A155 MEDROXYPROGESTERONE ACETATE 100MG TABLET 4,200 24,456 13,295 A172 MEXILETINE HCL 200MG CAPSULES 1,680 2,296 A176 METOCLOPRAMIDE 10MG TABLET 59,892 167,208 72,894 A179 NAPROXEN 250MG TABLET 56,636 158,316 26,261 A184 NITROFURANTOIN 50MG CAPSULE 11,220 77,112 37,419 A188 OESTROGENS CONJUGATED 0.625MG TABLET 1,764 9,696 7,716 A202 PHENOXYMETHYLPENICILLIN 250MG TABLET 44,408 277,416 141,997 A210 POTASSIUM CHLORIDE 600MG TABLET MR 230,000 1,169,184 771,093 A213 PREDNISOLONE 5MG TABLET 77,700 373,740 229,036 A227 PYRAZINAMIDE 500MG TABLET 4,900 22,872 9,911 A228 PYRIDOSTIGMINE BROMIDE 60MG TABLET 34,000 183,888 125,695 A231 PYRIMETHAMINE 25MG TABLET 450 1,656 1,523 A001 ACETAZOLAMIDE 250MG TABLET 81,000 418,308 234,470 A005 ACITRETIN 25MG CAPSULE 1,980 24,732 11,748 A007 ALFACALCIDOL 0.25µ CAPSULE 44,460 657,924 490,429 A010 CO-AMILOZIDE 5MG|50MG TABLET 45,164 766,584 557,836 A011 AMIODARONE HYDROCHLORIDE 200MG TABLET 262,900 961,404 457,048 A019 ATENOLOL 100MG TABLET 971,644 4,205,088 2,769,040 A025 TRIHEXYPHENIDYL HYDROCHLORIDE 2MG TABLET 359,000 1,414,392 524,536 A027 BISACODYL 5MG TABLET GASTRO-RES 27,000 55,104 33,841 A032 BUMETANIDE 1MG TABLET 2,039,860 11,844,384 7,704,014 A033 BUMETANIDE 5MG TABLET 29,848 100,116 52,792 A040 CAPTOPRIL 50MG TABLET 1,140 A041 CARBAMAZEPINE [TEGRETOL] 200MG TABLET 223,800 2,127,468 703,411 A045 CEPHALEXIN 250MG TABLET/CAPSULE 5,344 18,924 11,235 A065 CO-TRIMOXAZOLE 480MG TABLET 24,882 163,944 84,530 A070 CYPROTERONE ACETATE 50MG TABLET 15,232 66,108 18,816 A071 DANAZOL 200MG CAPSULE 780 725 A075 DEXAMETHASONE 0.5MG TABLET 10,200 65,100 37,467 A079 DILTIAZEM HYDROCHLORIDE 60MG TABLET 45,700 263,148 132,343 A093 ERYTHROMYCIN 250MG TABLET/CAPSULE 11,620 26,532 10,355 A102 ORAL IRON PROVIDING 65-70MG TABLET 72,600 860,796 500,944 A103 BEZAFIBRATE 400MG TABLET MR 187,200 771,384 607,761 A105 FLUCLOXACILLIN 250MG CAPSULE 9,559 105,192 68,874 A106 FLUDROCORTISONE ACETATE 0.1MG TABLET 23,250 62,604 40,633 *Annual Consumption - calculated Pro-rata based on the consumption of the first five months of 2017 A110 FOLIC ACID 5MG TABLET 298,140 1,501,236 1,495,291 A114 GLIBENCLAMIDE 5MG TABLET 293,524 906,048 455,230 A118 GRISEOFULVIN 125MG TABLET 5,680 12,540 2,079 A123 HYDRALAZINE HYDROCHLORIDE 25MG TABLET 14,000 1,055,700 599,470 A125 HYDROXYCHLOROQUINE SULFATE 200MG TABLET 18,780 333,960 180,421 A126 HYDROXYCARBAMIDE 500MG CAPSULE 15,400 181,044 158,086 A129 IBUPROFEN 200MG TABLET 46,872 245,880 113,358 A145 CO-BENELDOPA 100MG|25MG CAPSULE 24,730 113,412 51,840 A232 PYRIMETHAMINE & SULFADIOXINE 25MG|250MG TABLET 3 12 A238 RIFAMPICIN & ISONIAZID 150MG|100MG TABLET 1,680 11,028 6,701 A242 SENNA 7.5MG TABLET 75,000 492,588 355,573 A247 DIETHYLSTILBESTROL 1MG TABLET 1,344 10,008 4,805 A254 TAMOXIFEN 20MG TABLET 450 568,008 343,148 A267 THYROXINE SODIUM 100µ TABLET 691,992 1,708,020 1,123,997 A295 CICLOSPORIN [NEORAL] 25MG CAPSULE 38,050 195,432 125,961 A306 MEFLOQUINE 250MG TABLET 208 132 1,122 A308 NIFEDIPINE 20MG TABLET/CAPSULE MR 37,300 210,348 118,038 A312 OXYBUTYNIN HYDROCHLORIDE 5MG TABLET 8,988 145,716 105,787 A317 ZIDOVUDINE 100MG CAPSULE 9,340 23,256 4,496 A319 ZUCLOPENTHIXOL ACETATE 10MG TABLET 3,100 7,680 4,834 A321 LEFLUNOMIDE 20MG TABLET 3,510 46,680 29,079 A324 FINASTERIDE 5MG TABLET 3,532 24,384 14,948 A328 TRETINOIN 10MG CAPSULE 700 5,748 2,175 A331 FLUVASTATIN 40MG CAPSULE 819,600 3,793,788 2,495,295 A334 LEVOFLOXACIN 500MG TABLET 2,635 33,300 20,583 A347 SIMVASTATIN 10MG TABLET 243,068 756,300 496,854 A348 ACYCLOVIR 200MG TABLET 6,450 305,880 149,807 A366 METYRAPONE 250MG CAPSULE 1,900 6,526 A376 QUININE SULFATE 300MG TABLET 3,528 25,992 9,882 A377 ALLOPURINOL 300MG TABLET 15,316 777,552 430,052 A391 OMEPRAZOLE 20MG TABLET GASTRO-RES 2,550,108 1,556,400 11,156,324 A393 CALCITRIOL 0.5µ CAPSULE 1,560 2,030 A401 FLUCONAZOLE 150MG CAPSULE 1,561 1,920 829 A404 LINEZOLID 600MG TABLET 150 600 242 A406 CO-BENELDOPA 25MG|100MG TABLET DISPERSIBLE 18,600 61,440 27,556 A424 CO-CARELDOPA [SINEMET CR] 50MG CAPSULE PROL-REL 480 1,160 A426 NALTREXONE HYDROCHLORIDE 50MG TABLET 1,512 26,736 17,138 A430 PAROXETINE 20MG TABLET 1,888,710 5,656,068 3,631,847 A444 FISH OIL 1000MG CAPSULES 1,230 1,305 A146 CO-BENELDOPA 200MG|50MG CAPSULE 1,100 7,212 1,934 A151 MAPROTILINE HYDROCHLORIDE 25MG TABLET 5,000 27,324 12,086 A157 MELPHALAN 2MG TABLET 275 900 1,571 A163 METFORMIN HYDROCHLORIDE 500MG TABLET 9,892,600 1,242,192 28,893,995 A165 METHOTREXATE 2.5MG TABLET 79,700 449,472 617,116 A166 METHOXSALEN 10MG TABLET 3,350 5,400 7,010 A169 METOPROLOL TARTRATE 50MG TABLET 9,632 189,228 169,926 A173 MIANSERIN HYDROCHLORIDE 10MG TABLET 38,000 211,380 111,192 A199 PENECILLAMINE 250MG TABLET 168 6,084 6,130 A220 PROMETHAZINE HYDROCHLORIDE 10MG TABLET 22,011 74,688 15,432 A223 PROPRANOLOL HYDROCHLORIDE 10MG TABLET 16,800 612,876 348,563 A230 PYRIDOXINE HYDROCHLORIDE 50MG TABLET 3,278 27,360 13,943 A237 RIFAMPICIN 300MG TABLET 10,300 31,848 17,404 A240 SALBUTAMOL 4MG TABLET 1,750 5,664 A243 SODIUM BICARBONATE 500MG/600MG TABLET 15,960 112,464 77,970 A255 TETRABENAZINE 25MG TABLET 22,848 223,200 123,181 A260 THIAMINE HYDROCHLORIDE 50MG TABLET 106,200 649,692 352,672 *Annual Consumption - calculated Pro-rata based on the consumption of the first five months of 2017 A274 TRIMETHOPRIM 100MG TABLET 1,387 6,348 2,707 A281 VITAMIN A & D CAPSULES 79,000 357,768 236,887 A285 WARFARIN SODIUM 1MG TABLET 268,604 2,118,252 1,400,275 A286 WARFARIN SODIUM 3MG TABLET 321,244 1,735,776 1,231,273 A309 NORFLOXACIN 400MG TABLET 5,866 19,932 4,095 A327 GLICLAZIDE 80MG TABLET 2,848,596 397,812 7,276,804 A332B SIMVASTATIN 20MG TABLET 7,608,048 456,072 14,990,777 A336 FLUVOXAMINE MALEATE 100MG TABLET 175,410 1,297,524 721,250 A337 EFAVIRENZ 600MG TABLET 11,010 47,220 26,469 A342 RISPERIDONE 1MG TABLET 78,800 1,355,748 747,887 A349 ACYCLOVIR 800MG TABLET 3,395 10,224 4,315 A355 CLONIDINE HYDROCHLORIDE 100µ TABLET 7,600 57,504 37,950 A367 NICLOSAMIDE 0.5G TABLET 104 36 48 A379 ACETYLSALICYLIC ACID 75MG-100MG TABLET GASTRO-RES 4,204,850 11,298,552 10,058,312 A004 ACETYLSALICYLIC ACID 300MG TABLET DISPERSIBLE 3,386 19,068 5,792 A006 ALLOPURINOL 100MG TABLET 228,620 1,739,388 1,693,204 A009 AMANTADINE HYDROCHLORIDE 100MG TABLET/CAPSULE 14,800 84,396 35,050 A014 CO-AMOXICLAV 250MG|125MG TABLET 66,314 397,236 304,715 A020A ATROPINE SULFATE 500MCG TABLET 1,600 4,560 6,768 A021 AZATHIOPRINE 50MG TABLET 64,000 938,268 518,252 A030 BROMOCRIPTINE MESYLATE 2.5MG TABLET 21,510 134,352 54,387 A039 CAPTOPRIL 25MG TABLET 4,920 49,140 28,842 A046 CHLORAMBUCIL 2MG TABLET 1,254 3,660 3,495 A049 CHLOROQUINE PHOSPHATE 250MG TABLET 80 276 193 A052 CHLORPROMAZINE HYDROCHLORIDE 25MG TABLET 130,400 360,480 210,298 A058 CLINDAMYCIN 150MG TABLET/CAPSULE 80,386 181,308 110,549 A060 CLOMIFENE CITRATE CITRATE 50MG TABLET 30 A061 CLOMIPRAMINE HYDROCHLORIDE 10MG TABLET 90,472 469,716 389,008 A066 CYCLIZINE HYDROCHLORIDE 50MG TABLET 6,500 39,852 21,272 A074 DAPSONE 100MG TABLET 4,536 12,312 48,731 A076 DICLOFENAC POTASSIUM 25MG TABLET GASTRO-RES 194,968 1,096,560 839,384 A082 DIPYRIDAMOLE 100MG TABLET 385,000 3,773,568 2,390,629 A083 DISOPYRAMIDE 100MG CAPSULE 2,772 19,932 7,310 A090 ENALAPRIL MALEATE 5MG TABLET 1,188,900 7,734,984 5,057,788 A091 ENALAPRIL MALEATE 20MG TABLET 1,731,268 4,493,400 2,426,539 A097 ETHOSUXIMIDE 250MG CAPSULE 12,750 15,588 8,576 A104 FLECAINIDE ACETATE 100MG TABLET 16,020 169,392 99,638 A124 HYDROCORTISONE 20MG TABLET 31,460 55,980 113,416 A128 HYOSCINE BUTYLBROMIDE 10MG TABLET 58,000 168,084 65,265 A132 INDOMETACIN 25MG CAPSULE 2,016 20,088 5,618 A133 IRON & FOLIC ACID 90-105MG|350-1000µ TABLET/CAPSULE 10,650 81,540 75,659 A135 ISONIAZID 100MG TABLET 1,972 15,240 11,893 A140 LABETOLOL HYDROCHLORIDE 100MG TABLET 43,250 129,192 41,093 A141 LABETALOL HYDROCHLORIDE 200MG TABLET 23,500 116,832 80,977 A144 CO-BENELDOPA 50MG|12.5MG CAPSULE 6,700 63,204 28,523 A446 SULINDAC 200MG TABLET 392 1,615 A453 DOMPERIDONE 10MG TABLET 22,200 167,460 77,883 A472A PRAZIQUANTEL 600MG TABLET 36 48 29 A482 ATENOLOL 25MG TABLET 1,173,508 3,998,328 2,559,873 A490 DOXAZOSINE MESYLATE 1MG TABLET 5,294 238,656 168,528 A501 DIAZOXIDE 50MG TABLET 3,800 9,185 A507 TACROLIMUS 5MG CAPSULE 1,000 5,460 2,659 A510 LISINOPRIL 5MG TABLET 13,384 83,976 46,092 A511 LISINOPRIL 10MG TABLET 28,140 433,212 161,083 A523 FLUDARABINE PHOSPHATE 10MG TABLET 660 1,500 2,030 A536 ESTRADIOL & NORGESREL 2MG/0.5MG TABLET
Load more

Recommended publications
  • Argon Medical Devices Products Catalogue
    ARGON PRODUCTS CATALOGUE Argon Medical Devices Products Catalogue WWW.ARGONMEDICAL.EU.COM www.argonmedical.eu.com[ 1 ] ARGON PRODUCTS CATALOGUE WWW.ARGONMEDICAL.EU.COM [ 2 ] [ 3 ] ARGON PRODUCTS CATALOGUE Table of Contents Thrombus Management .....................................................5 Endomyocardial Biopsy ................................................... 63 • Option™ELITE Inferior Vena Cava Filter System ....................6 • Jawz™ Endomyocardial Biopsy (EMB) Forceps ................... 64 • Atrieve™ Vascular Snare Kit ����������������������������������������������������8 • Endomyocardial Biopsy Accessories ���������������������������������� 65 • V+Pad™ Hemostasis Pads ......................................................9 • CLEANERXT™ & CLEANER15™ Rotational Thrombectomy System ................................................................................. 10 Bone & Bone Marrow Biopsy .......................................... 67 • T-Lok™ Bone Marrow Biopsy Needles ................................. 68 • Bone Marrow Aspiration Needles....................................... 68 Drainage ............................................................................13 • Bone Marrow Harvest Needles .......................................... 69 • SKATER™ Single Step Drainage Catheters ......................... 15 • Pediatric Bone Marrow Access Needles ............................ 69 • SKATER™ Drainage Catheters ............................................. 16 • Osty-Core™ Bone Biopsy Needles ......................................
    [Show full text]
  • Contemporary Methods for the Treatment of Pulmonary Embolism — Is It Prime-Time for Percutaneous Interventions?
    Kardiologia Polska 2017; 75, 11: 1161–1170; DOI: 10.5603/KP.a2017.0125 ISSN 0022–9032 ARTYKUŁ SPECJALNY / STATE-OF-THE-ART REVIEW Contemporary methods for the treatment of pulmonary embolism — is it prime-time for percutaneous interventions? Marcin Kurzyna1, Arkadiusz Pietrasik2, Grzegorz Opolski2, Adam Torbicki1 1Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology, European Health Centre Otwock, Centre of Postgraduate Medical Education, Otwock, Poland 2Department and Faculty of Cardiology, Medical University of Warsaw, Warsaw, Poland Marcin Kurzyna, MD, PhD. Since 1998 he has been a physician in the Intensive Care Unit, and since 2003 the Head of the Haemodynamic Lab in the National Institute for Lung Diseases. Cur- rently he is Deputy Head of the Department of Pulmonary Circulation, Thromboembolic Diseases, and Cardiology and an associate professor in the Centre of Postgraduate Medical Education in Warsaw. He was a Chairman of Working Group on Pulmonary Circulation of Polish Cardiac Society (2013–2015). He is a specialist in internal medicine and cardiology and has a PhD in respiratory medicine. His research interests are currently related to the role of invasive procedures in the diagnosis and treatment of pulmonary vascular diseases. Arkadiusz Pietrasik, MD, PhD is an assistant in the First Chair and Department of Cardiology, Medical University of Warsaw. He is an independent operator certified by the Association of Car- diovascular Interventions (AISN) of the Polish Cardiac Society. His research interests cover structural heart diseases, coronary artery diseases, intravascular visualisation techniques, and chronic throm- boembolic pulmonary hypertension. He is a coordinator of the Pulmonary Embolism Response Team (CELZAT) at the Central Clinical Hospital of the Medical University of Warsaw.
    [Show full text]
  • Annual Meeting Delegate Handbook
    BSIR 2016 ANNUAL MEETING DELEGATE HANDBOOK 1 5TH-1 7TH NOVEMBER 2016 MANCHESTER CENTRAL MANCHESTER 1 MAJOR SPONSORS 2 CONTENTS PAGE CONTENTS 4 Welcome to BSIR 2016 5 Speaker Instructions 6-7 General Information & Social Events WEDNESDAY 4TH NOVEMBER 2015 9 Programme Day 1 10 Scientific Sessions 1 & 2 11 The Graham Plant Proessorship 2016 12 SIRNR Programme 13 Industry Showcases 14 Masterclasses & Workshops THURSDAY 5TH NOVEMBER 2015 15 Programme Day 2 16 Scientific Sessions 3 & 4 17 OOH Intervention Snapshot Survey 18 Masterclasses & Workshops 19 Industry Showcases FRIDAY 6TH NOVEMBER 2015 20 Programme Day 3 21 Scientific Sessions 5 & 6 22 BSIR/BSIRT Trainee Day Programme 24 BSIR Honorary Fellowships: Professor Mike Dake & Dr Giles Maskell 25 BSIR Gold Medal: Professor Anthony Watkinson 26 Wattie Fletcher Lecture: Dr Richard McWilliams 27 Graham Plant Lecturer 28-29 Faculty Biographies 30-31 Faculty Lists 32-33 Exhibition Plan 34 List of Exhibitors 36-46 Exhibitor Bios 48-49 SIRNR Section 50 BSIR AGM 53-61 BSIR Committee Reports 62 BSIR Membership Form 64-69 BSIR/BSIRT Trainee Day Essay Scholars 70-75 BSIR Abstract & Case Study Review 76 VASBI 2017 - Trainee Day Meeting Announcement 77-100 BSIR Abstracts - Scientific Sessions 1-6 101 VASBI 2017 - Meeting Announcement 102-107 BSIR Scientific & Educational Posters 108 The U Foundation 109 BSIR 2017 - Meeting Announcement 110 BSIR IOUK 2017 - Meeting Announcement 3 WELCOME TO BSIR 2016 Dear Colleagues, The theme of this year scientific program continues from the last year’s one which entails covering the widest possible aspects of interventional radiology within the limited conference time.
    [Show full text]
  • NUMC-CDM-Jan2019.Pdf
    Charge Code Charge Description Charge 0301001 D.R.Ceaserean Sect $11,302.20 0301002 D.R. D&C $2,692.50 0301003 D.R. Insert Lamnaria $873.81 0301004 D.R. Salting $1,626.87 0301005 D.R. Vag Delivery $8,073.00 0301009 D.R. Prep Room Visit $383.62 0301010 D.R.Pstprtm Tubal Lg $2,749.34 0301011 D.R.Shirodkar $3,892.36 0301012 D.R. H.I.P. Laser Tr $838.30 0301013 D.R. H.I.P. Cryothrp $838.30 0301014 D.R. Vbac $3,500.77 0301015 D.R. C/S After Attempt Vbac $3,648.06 0301016 D.R. Low Forceps Delivery $9,149.40 0301017 D.R. Vacuum Assisted Delivery $9,149.40 0301018 Dr Del. Other Ntrl/Artfcl Open $9,149.40 0302001 L.R. Nst/Oct Intl Te $547.02 0302002 L.R. Nst/Oct Sbsq Te $500.00 0302050 Antepartum Care 7> Visits Only $1,666.26 0401001 P-F Spromtry Vol Vnt $427.34 0401002 Spirometry Bef&Aft Bronchdilat $788.64 0401005 P-F Diffus(Sin.Brth) $438.03 0401006 P-F Flow Vol Loop $725.49 0401010 P-F Compliance Study $1,387.63 0401012 P-F Art Punc&Bld Col $315.70 0401013 P-F Intr Arterial Ca $320.77 0401016 P-F Laryn&Trachescpy $1,234.64 0401017 P-F Bronchoscopy $3,979.48 0401018 P-F Brnchscpy&Brshng $3,979.48 0401019 Bronchoscopy W/Biopsy(S) $3,979.48 0401020 P-F Brnc&Biop&Brshng $3,979.48 0401021 Bronchoscopy/Lung Bx Each $7,863.33 0401022 P-F Trnsthor Ne Biop $4,051.10 0401023 P-F Pleural Biopsy $4,051.10 0401034 P-F Bronc Provac Tst $725.49 0401035 ASPIRATE PLEURA W/O IMAGING $2,152.80 0401044 Bronchoscopy/Needle Bx Each $6,558.51 0401046 P-F Lungfunc Mbc/Mvv $300.32 0401048 P-F Airway Inhal Trt $491.92 0401051 P-F Pos Airway Press $491.92 0401054 P-F
    [Show full text]
  • IDEAS 2015 Pocket Guide General Information
    Interdisciplinary Endovascular Aortic Symposium IDEAS 2015 September 27-29 Lisbon/Portugal Interdisciplinary Endovascular Aortic Symopsium POCKET GUIDE POCKET GUIDE POCKET 2015 EAS INNOVATION | EDUCATION | INTERVENTION Cardiovascular and Interventional Radiological Society of Europe ID Scientific & Educational Programme * Corporate Activities 4 General Information from A to Z 10 Session Types Sunday - Scientific Programme 11 SUN Monday - Scientific Programme 14 MON Tuesday - Scientific Programme 17 TUE 19 Corporate Activities 22 Satellite Symposia 39 Learning Centres 48 Technical Exhibition 48 Alphabetical & Numerical List 54 Technical Exhibitors Guide 110 Radiation Protection Pavilion 124 Floor Plans * advertisement-free section in accordance with the document UEMS 2012/30 – the Accreditation of Live Educational Events of the EACCME® (article 33/34) Cardiovascular and Interventional Radiological Society of Europe Welcome Address Welcome to the inaugural IDEAS symposium! Keep an eye out for the Endovascular aortic therapies have long been of interest to in- CIRSE Society app update terventional radiologists, vascular surgeons and cardiologists alike – the option to treat the aorta in a minimally invasive New features and design in time for CIRSE 2015! way opens exciting therapeutic possibilities, but realising this dream has been anything but straightforward. Install the CIRSE 2015 event to ensure your access to the best toolkit for the Annual Meeting in Lisbon: Recent technological advances have brought with them fresh enthusiasm for minimally invasive repair of aortic aneurysms – a complex category of interventions that rely heavily on the skills of a well-trained multidisciplinary medical team. • New! paperless session evaluation The various professionals involved in this team all bring their • e-voting own essential skills to the table.
    [Show full text]
  • Percutaneous Transfemoral Repositioning of Malpositioned Central Venous Access Device: a Report of Two Cases
    Free full text available from Case Report www.cancerjournal.net Percutaneous transfemoral repositioning of malpositioned central venous access device: A report of two cases ABSTRACT Ashutosh Chauhan, 1 Placement of long term central venous access devices (CVAD) such as chemo ports and Hickman’s catheters are associated with a Kamal Pathak , Manomoy Ganguly definite risk of catheter tip malpositioning. As such, malpositioning runs a risk of venous thrombosis and related complications; it is imperative to reposition the catheter. Percutaneous transfemoral venous approach has been described as a minimally invasive and Departments of safe method for the repositioning. We present two cases in which the CVAD implanted in one subclavian vein got malpositioned in Surgical Oncology and 1Interventional Radiology, contra lateral subclavian vein. A percutaneous transfemoral venous approach utilizing 5 Fr angiographic catheter was successful in Army Hospital (R &R), repositioning of the catheters in both cases. Delhi, India For correspondence: Dr. Ashutosh Chauhan, KEY WORDS: Chemo port, Hickman’s catheter, malposition, repositioning Department of Surgical Oncology, Army Hospital (R &R), Delhi Cantt, Delhi-110 010, India. INTRODUCTION undergone modified radical mastectomy and was E-mail: bolubonkey@ referred to our Center for placement of chemo port rediffmail.com Long term Central Venous Access Devices (CVAD) to facilitate the planned adjuvant chemotherapy. A DOI: 10.4103/0973- are frequently utilized in oncological practice, chemo port was placed in the left subclavian vein 1482.63554 most commonly for chemotherapy and long term under general anesthesia using classical Seldinger PMID: ***** parenteral nutrition. CVAD insertion can be done technique. A check X-ray in the postoperative “blind” using the Seldinger technique or under period demonstrated that the catheter tip had radiological guidance, either by ultrasound or malpositioned into contra lateral subclavian fluoroscopy.[1] Malpositioning of the same is a vein [Figure 1a].
    [Show full text]
  • Perforation of the Great Vessels During Central Venous Line Placement
    Arch Intern Med. 1995 Jun 12;155(11):1225-8. Perforation of the great vessels during central venous line placement. Robinson JF1, Robinson WA, Cohn A, Garg K, Armstrong JD 2nd. Author information Abstract BACKGROUND: Placement of central venous lines for the administration of a variety of therapies has become common practice. The most severe complication of this procedure is perforation of a large vessel, with bleeding, infusion of fluids into an extravascular site, and death. It is not clear from currently available data how often this occurs, what risk factors are associated, and how this complication can be avoided. METHODS: We reviewed the records of all patients who were identified as having perforation of a major vessel during central venous line placement occurring between 1986 and 1993 at the University Hospital, the major teaching facility of the University of Colorado Health Sciences Center, Denver. Data collected included the age and sex of the patient, diagnosis, type of catheter and site of placement, operator means and time to the diagnosis of perforation, and outcome. RESULTS: Eleven such complications were identified and 10 of them are reviewed in detail. The overall incidence was less than 1%. Most complications occurred when the right subclavian vein approach was attempted, and they were thought to result from guidewire kinking during advancement of a vessel dilator. All medical specialties and levels of training were involved. Four of 10 patients died of immediate or subsequent complications of the perforation. CONCLUSIONS: Perforation of a great vessel is an uncommon, but often fatal, complication of central venous line placement.
    [Show full text]
  • Pill That Shrinks Uterine Fibroids Gathers Early Data
    Mar Issue 17 65 App Suresh Vedantham: Pill that shrinks uterine Profile fibroids gathers early data Page 26 Ulipristal acetate has become the first oral therapy to show positive phase III esultsr for the treatment of uterine fibroids. In early 2017, it demonstrated efficacy and safety in the Michael Dake: treatment of uterine fibroids in two US pivotal studies. TEVAR’s dirty secret hree prominent physicians Page 28 who are strong advocates Tfor treating uterine fibroids using embolization: gynaecologist Bruce McLucas (California, USA) Lutonix AV results and interventional radiologists Jim Spies (Washington, DC, USA) provide tailwind for and Jon Moss (Glasgow, UK) tell Interventional News about how drug-coated balloons drugs will constantly nip at the heels of interventional treatments, and in dysfunctional how it is their side-effect profile that will determine whether patients will arteriovenous fistula tolerate their use. Ulipristal acetate is an treatment investigational drug for the medical treatment of uterine fibroids. It is Scott Trerotola presented the first release a selective progesterone receptor of eight-month data from the Lutonix AV modulator that acts directly on the trial at the Leipzig Interventional Course progesterone receptors in three target (LINC; 24–27 January, Leipzig, Germany) tissues: the endometrium; uterine Uterine fibromyoma and showed that the drug-coated balloon fibroids; and the pituitary gland. (Lutonix 035 AV from Bard) is linked with a Mclucas, who is founder of the In fact, leuprolide now markets a Richter announced positive results significantly higher target lesion patency Fibroid Treatment Collective and three month injection, rather than a from Venus II, the second of two and far fewer reinterventions to maintain whose team performed the first monthly one.
    [Show full text]
  • Transcatheter Creation of a Reverse Potts Shunt in a Patient with Severe Pulmonary Arterial Hypertension Associated with 2015;11: 121 Moyamoya Syndrome
    IMAGE IN CARDIOLOGY INTERVENTIONS FOR HYPERTENSION AND HEART FAILURE Euro Intervention Transcatheter creation of a reverse Potts shunt in a patient with severe pulmonary arterial hypertension associated with 2015;11: Moyamoya syndrome 121 Dietmar Schranz*, MD; Gunter Kerst, MD; Thilo Menges, MD; Hakan Akintürk, MD; Inge van Alversleben, MD; Stefan Ostermayer, MD; Christian Apitz, MD; Axel Moysich, MD Pediatric Heart Center, Justus-Liebig University Hospital, Giessen, Germany This paper also includes accompanying supplementary data published online at: http://www.pcronline.com/eurointervention/84th_issue/21 A palliative Potts shunt is already used for the treatment of drug- Figure 2, Online Appendix and Moving image 1-Moving image 8. refractory pulmonary arterial hypertension (PAH). We report on The risk/benefit of creating a transcatheter Potts shunt needs to be a transcatheter Potts shunt creation in a 19-year-old patient with confirmed in further studies. PAH and Moyamoya syndrome. He was admitted with haemopty- sis and end-stage right ventricular failure. The technique consisted Conflict of interest statement of retrograde radiofrequency perforation of the descending aorta The authors have no conflicts of interest to declare. at the side of apposition to the left pulmonary artery for deploy- ment of a 7 Fr, 22 mm long graft stent. Depicted are the final axial Online data supplement (Figure 1A) and coronal (Figure 1B) computed tomography (CT) Online Appendix. Transcatheter Potts shunt creation. images demonstrating the covered stent expanded to 7 mm, posi- Online Figure 1. Echocardiography in four-chamber view. tioned between the left pulmonary artery (LPA) and descending Online Figure 2. Step-by-step transcatheter Potts shunt creation.
    [Show full text]
  • Tackling the Challenges in the Vascular and Endovascular Arena
    CHARING CROSS SPECIAL EDITION March 2016 2016 Vascular & Endovascular Challenges Update Tackling the challenges in the vascular and endovascular arena Peripheral Acute Aortic Venous Arterial Stroke Challenges Challenges Challenges Challenges Halfway through its Controversies, Challenges and Consensus allow the audience to interact with the Challenges Programme—new as of cycle, the Charing Cross Symposium will examine this year the speakers and panel at every stage. 2016—will make its debut. The half-day numerous and varied challenges currently facing the vascular This year, the CX Venous Challenges Programme is being introduced following and endovascular field. The Symposium will be held from 26 to 29 Main Programme will, for the first time, the realisation that a number of strokes April 2016 at Olympia Grand, London, UK. take place on the Symposium’s opening are caused by interventions in the aorta day, exploring the use of various technolo- and manipulations in the arch. his year’s Peripheral Arterial aortic aneurysm trial to be conducted, gies and techniques for the treatment of The purpose of the Acute Stroke Chal- Challenges session will centre and the first to reach fifteen-year follow- superficial and deep venous disease with lenges Main Programme is to encourage around management of the up. The 10-year data, presented at CX emphasis on the latest evidence of when a multidisciplinary approach, such that superficialT femoral artery. Treatment 2010, demonstrated no significant dif- and in which patients they should be used. unwanted emboli to the brain can be man- strategies, varying depending on lesion ferences between endovascular and open The topics for discussion will include aged by clot retrieval, and the optimisation type and length, will be analysed, with repair in terms of mortality.
    [Show full text]
  • Brachial Approach As an Alternative Technique of Fibrin Sheath Removal for Implanted Venous Access Devices
    CASE REPORT published: 10 April 2017 doi: 10.3389/fsurg.2017.00020 Brachial Approach As an Alternative Technique of Fibrin Sheath Removal for Implanted Venous Access Devices Charalampos Sotiriadis*, Steven David Hajdu, Francesco Doenz and Salah D. Qanadli Lausanne University Hospital, Lausanne, Switzerland Implanted venous access device (IVAD) late dysfunction is commonly caused by fibrin sheath formation. The standard method of endovascular fibrin sheath removal is per- formed via the femoral vein. However, it is not always technically feasible and sometimes contraindicated. Moreover, approximately 4–6 h of bed rest is necessary after the proce- dure. In this article, we describe an alternative method of fibrin sheath removal using the brachial vein approach in a young woman receiving chemotherapy for breast cancer. The right basilic vein was punctured, and a long 6°F introducer sheath was advanced into the right subclavian vein. Endovascular maneuvers consisted on advancing Atrieve™ Edited by: Vascular Snare 15–9 mm after catheter insertion in the superior vena cava through a Konstantinos A. Filis, University of Athens Medical 5.2°F Judkins left catheter. IVAD patency was restored without any complication, and School, Greece the patient was discharged immediately after the procedure. In conclusion, fibrin sheath Reviewed by: removal from an obstructed IVAD could be performed via the right brachial vein. Further Andreas M. Lazaris, National and Kapodistrian research is necessary in order to prove efficacy of this technique. University of Athens, Greece Thodur Madabushi Vasudevan, Keywords: brachial access, fibrin sheath removal, implanted venous access devices, vein, endovascular treatment Waikato Hospital, New Zealand *Correspondence: Charalampos Sotiriadis INTRODUCTION [email protected] The use of implanted venous access devices (IVADs) has significantly improved the quality of life in Specialty section: patients requiring long-term intravenous therapy (1).
    [Show full text]
  • Argon Medical Devices Product Catalog
    ARGON PRODUCT CATALOG Argon Medical Devices Product Catalog WWW.ARGONMEDICAL.COM www.argonmedical.com[ 1 ] ARGON PRODUCT CATALOG Table of Contents About Argon Medical Devices, Inc. Argon Medical Devices, Inc. is a global manufacturer of specialty medical products headquartered in Plano, Texas. Argon offers a broad line of medical devices for Interventional Radiology, Vascular Surgery and Interventional Cardiology. Argon has successfully grown into a leading global supplier of devices to the healthcare marketplace. Argon’s brand is recognized for producing quality products that improve patient outcomes. Our products include the Option™ELITE Retrievable Inferior Vena Cava Filter, Cleaner™ Rotational Thrombectomy Systems, and UltraStream™ Chronic Dialysis Catheter. We also offer complete lines of PICC and midline catheters, endomyocardial biopsy forceps, introducer sheaths, pressure transducers, and other vascular products. Following the acquisition of Angiotech Pharmaceuticals Interventional business in April 2013, Argon Medical Devices also offers a variety of devices for biopsy, drainage and vascular procedures. Key product lines in this business include BioPince™ Full Core Biopsy Devices, Tru-Core™ II (fully automatic) and SuperCore™ (semi-automatic) Disposable Biopsy Instruments, T-Lok™ Bone Marrow Biopsy Devices, Skater™ Drainage Catheters, and Atrieve™ Vascular Snare. Argon’s established sales and marketing infrastructure serves a broad and diversified global customer base through both a direct sales force, and through long-standing relationships with OEMs, strategic partners, and leading medical device distributors. For more information, or to be contacted by your local Territory Manager, please contact Argon Customer Service at 800.927.4669, fax 903.677.9396 or email [email protected] WWW.ARGONMEDICAL.COM [ 2 ] ARGON PRODUCT CATALOG Table of Contents Thrombus Management.....................................................5 HSG & Prostate .................................................................
    [Show full text]